ChiCTR-TRC-14004233已完成不适用
晶體切除手術或內鏡光凝激光聯合晶體切除手術用於治理慢性原發性閉角型青光眼之研究
Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2014年2月13日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- The primary outcome measures are IOP and the number of IOP-lowering drugs.
研究概览
简要总结
晶體切除手術或內鏡光凝激光聯合晶體切除手術用於治理慢性原發性閉角型青光眼
研究设计
- 研究类型
- 干预性研究
- 主要目的
- 随机平行对照
入排标准
- 年龄范围
- 18 至 —（—）
- 性别
- All
入选标准
- •A diagnosis of PACG;
- •Requiring 2 or more IOP-lowering drugs to control IOP, or IOP >21mmHg on maximally tolerable drugs;
- •Able and willing to give informed consent, prior to randomization;
- •Older than 18 years of age.
排除标准
- •Previous intraocular surgery or cyclophotocoagulation, with the exception of laser peripheral iridotomy and argon laser peripheral iridoplasty;
- •Secondary causes of angle closure including iridocorneal-endothelial syndrome, neovascular glaucoma etc.;
- •Unable to cooperate for reliable visual field and OCT examination.
研究组 & 干预措施
Experimental group
-Combined Phacoemulsification-Endoscopic Cyclophotocoagulation(Phaco-ECP) -Phacoemulsification, for two years
Contro group
Phaco-ECP, Phacoemulsification to remove the cataratous lens and insertion of an intraocular lens and endoscopic cyclophotocoagulation to ablate the ciliary processes to reduce aqueous production and achieve further IOP reduction.
结局指标
主要结局
The primary outcome measures are IOP and the number of IOP-lowering drugs.
次要结局
- Secondary outcome measures include BCVA, surgical complications, and need for additional surgical interventions.
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
平板袢人工晶状体在青白联合术后效果的观察ChiCTR2300069056白求恩公益基金会
Unknown
不适用
内窥镜下房角分离联合超声乳化术与小梁切除联合超声乳化术治疗闭角型青光眼合并白内障的疗效观察ChiCTR2100049766无锡市第二人民医院雁阵人才“拔尖”60
Unknown
不适用
李寿玲医师：该研究的伦理审批文件未上传，请尽快上传并填写伦理审批日期。 25G 玻璃体切割术治疗人工晶体眼恶性青光眼的安全性及有效性观察：基于病历记录的回顾性分析恶性青光眼ChiCTR1900025126自筹20
Unknown
不适用
微小透镜基质切除术与有晶体眼人工晶体植入术的术后视觉质量比较与临床研究ChiCTR-IOR-16008647院科研基金80
Unknown
不适用
飞秒激光辅助角膜缘松解切开术与 Toric 人工晶体植入术矫正白内障患者角膜散光比较研究ChiCTR2100051066国家自然科学基金（820709398）220